metricas
covid
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Utilidad de atazanavir en poblaciones especiales
Información de la revista
Vol. 26. Núm. S17.
Atazanavir
Páginas 49-54 (diciembre 2008)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 26. Núm. S17.
Atazanavir
Páginas 49-54 (diciembre 2008)
Acceso a texto completo
Utilidad de atazanavir en poblaciones especiales
Utility of atazanavir in special populations
Visitas
1925
Antonio Antela López
Autor para correspondencia
antonio.antela.lopez@sergas.es

Correspondencia: Dr. A. Antela López. Unidad de VIH-Enfermedades Infecciosas. Servicio de Medicina Interna. Hospital Clínico Universitario de Santiago de Compostela. Avda. da Choupana, s/n. 15706 Santiago de Compostela. A Coruña. España.
Unidad de VIH-Enfermedades Infecciosas. Servicio de Medicina Interna. Hospital Clínico Universitario de Santiago de Compostela. La Coruña. España
Este artículo ha recibido
Información del artículo

En el momento actual, con el tratamiento antirretroviral (TAR) se consigue prolongar la supervivencia de las personas que viven con virus de la inmunodeficiencia humana (VIH) de forma indefinida. Debido a ello, nos encontramos cada vez con mayor frecuencia con problemas específicos que anteriormente no daba tiempo a desarrollar o no tenían la importancia que ahora alcanzan, y que configuran, a poblaciones especiales de pacientes. Ejemplos de situaciones que caracterizan a estas poblaciones especiales son: la coinfección por virus de la hepatitis B y/o C, el embarazo, la lipodistrofia, el riesgo cardiovascular, la insuficiencia renal, el tratamiento de los niños y adolescentes, la atención a personas desplazadas (inmigrantes) y el tratamiento de personas que estén recibiendo tratamiento sustitutivo con metadona, entre otras. En el presente artículo revisamos el papel que puede tener atazanavir en el TAR de pacientes en las situaciones mencionadas, excepto las que ya son tratadas específicamente en otros artículos, tal como la coinfección por virus de la hepatitis B y/o C.

Palabras clave:
Atazanavir
Embarazo
Lipodistrofia
Riesgo cardiovascular
Insuficiencia renal
Niños
Inmigrantes
Metadona

ART (antiretroviral therapy) currently continues to indefinitely prolong the survival of patients who live with HIV. Due to this, we are increasingly faced with specific problems that previously did not have time to develop or did not have the importance that they have now, and which are related to the existence of special patient populations. Examples of situations that characterise these special populations are: co-infection with hepatitis virus B and/or C, pregnancy, lipodystrophy, cardiovascular risk, renal failure, treatment of children and adolescents, immigrant health care, and the management of patients receiving methadone replacement therapy, among others. In this article we review the role that Atazanavir (ATV) can play in the ART of patients in the situations mentioned, except those that are already dealt with specifically in other articles, such as co-infection by hepatitis virus B and/or C.

Key words:
Atazanavir
Pregnancy
Lipodystrophy
Cardiovascular risk
Renal failure
Children
Immigrants
Methadone
El Texto completo está disponible en PDF
Bibliografía
[1]
P.M. Garcia, L.A. Kalish, J. Pitt, H. Minkoff, T.C. Quinn, S.K. Burchett, et al.
Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.
N Engl J Med, 341 (1999), pp. 394-402
[2]
J.P. Ioannidis, E.J. Abrams, A. Ammann, M. Bulterys, J.J. Goedert, L. Gray, et al.
Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads < 1000 copies/ml.
J Infect Dis, 183 (2001), pp. 539-545
[3]
D. Ripamonti, D. Cattaneo, F. Maggiolo, M. Airoldi, L. Frigerio, P. Bertuletti, et al.
Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
AIDS, 21 (2007), pp. 2409-2415
[4]
C. Ferreira, C. Floch-Tudal, F. Meier, G. Peytavin, J. Treluyer, V. Jullien, et al.
Atazanavir in pregnancy: influence on neonatal hyperbilirubinemia.
15th Conference on Retroviruses and Opportunistic Infections; february 3-6,
[5]
M. Natha, P. Hay, G. Taylor, G. Brook, L. Sarner, L. Cunningham, et al.
Atazanavir use in pregnancy: a report of 33 cases.
14th Conference on Retoviruses and Opportunistic Infections; february 25-28,
[6]
T. Eley, E. Vandeloise, M. Child, F. Conradie, C. Zorrilla, D. Josipovic, et al.
Steady state pharmacokinetics and safety of atazanavir after treatment with ATV 300 mg once-daily/ritonavir 100 mg once-daily + ZDV/3TC during the third trimester in HIV+ women.
15th Conference on Retroviruses and Opportunistic Infections; february 3-6,
[7]
DHHS Panel. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Diciembre, 2007. Disponible en: http://AIDSinfo.nih.gov
[8]
Recomendaciones de la SPNS/GESIDA/SEGO/AEP. Recomendaciones para el seguimiento de la infección por el VIH con relación a la reproducción, el embarazo y la prevención de la transmisión vertical 2007. Disponible en: www.gesida.seimc.org.
[9]
A. Carr, K. Samaras, S. Burton, Law, J. Freund, D.J. Chisholm, et al.
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
AIDS, 12 (1998), pp. F51-F58
[10]
J. Carr Millar, M. Law, D.A. Cooper.
A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.
AIDS, 14 (2000), pp. F25-32
[11]
T. Swainston Harrison, L.J. Scott.
Atazanavir: a review of its use in the management of HIV infection.
Drugs, 65 (2005), pp. 2309-2336
[12]
A. Nguyen, A. Calmy, V. Schiffer, E. Bernasconi, M. Battegay, M. Opravil, et al.
Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.
[13]
G. Haerter, B.J. Manfras, M. Mueller, P. Kern, A. Trein.
Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir.
AIDS, 18 (2004), pp. 952-955
[14]
N. Friis-Moller, C.A. Sabin, R. Weber, A. d’Arminio Monforte, W.M. El-Sadr, P. Reiss, et al.
Combination antiretroviral therapy and the risk of myocardial infarction.
N Engl J Med, 349 (2003), pp. 1993-2003
[15]
N. Friis-Moller, P. Reiss, C.A. Sabin, R. Weber, A. Monforte, W. El-Sadr, et al.
Class of antiretroviral drugs and the risk of myocardial infraction.
N Engl J Med, 356 (2007), pp. 1723-1735
[16]
EACS Guidelines. Disponible en: http://www.eacs.eu.
[17]
R. Murphy, I. Sanne, P. Cahn, P. Phanuphak, L. Percival, T. Kelleher, et al.
Doseranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naïve subjects: 48-week results.
[18]
M. Johnson, B. Grinsztejn, C. Rodríguez, J. Coco, E. DeJesus, A. Lazzarin, et al.
Atazanavir plus ritonavir or saquinavir and lopinavir/ritonavir in patients experiencing multiple virological failures.
AIDS, 19 (2005), pp. 685-694
[19]
M. Johnson, B. Grinsztejn, C. Rodríguez, J. Coco, E. DeJesus, A. Lazzarin, et al.
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ ritonavir in patients with multiple virological failures.
[20]
U. Möbius, M. Lubach-Ruitman, B. Castro-Frenzel, M. Stoll, S. Esser, E. Voigt, et al.
Switching to atazanavir improves metabolic disorders in antiretroviral- experienced patients with severe hyperlipidemia.
J Acquir Immune Defic Syndr, 39 (2005), pp. 174-180
[21]
J.M. Molina, J. Andrade-Villanueva, J. Echevarria, P. Chetchotisakd, J. Corral, N. David, et al.
Eficacy and safety of once-daily Atazanavir/ritonavir compared to twice-daily Lopinavir/ritonavir, each in combination with Tenofovir and Emtricitabine in ARV-naïve HIV-1-infected subjects: the CASTLE study, 48-week results.
15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 3-6 febrero,
[22]
M.A. Noor, O.P. Flint, J.F. Maa, R.A. Parker.
Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.
[23]
J. Jemsek, E. Arathoon, M. Arlotti, C. Perez, N. Sosa, V. Pokrovskiy, et al.
Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine in antiretroviral naïve HIV-infecetd patients.
Clin Infect Dis, 42 (2006), pp. 273-280
[24]
S. Agarwala, T. Eley, M. Child, Y. Wang, A. Persson, D. Filoramo, et al.
Pharmacokinetics of Atazanavir in severely renally impaired subjects including those on hemodialysis.
8th International Workshop on Clinical Pharmacology of HIV Therapy,
[25]
T. Meyers, R. Rutstein, P. Samson, A. Violari, M. Palmer, J. Kiser, et al.
Treatment responses to Atazanavir-containing HAART in a drug-naïve paediatrics population in South Africa.
15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 3-6 Febrero,
[26]
ONUSIDA/07.
Situación de la epidemia de SIDA (versión española, diciembre de 2007).
OMS, (2007),
[27]
Encuesta hospitalaria de pacientes VIH/SIDA. Resultados 2006. Análisis de la evolución 1996-2006. Disponible en: http://www.msc.es/ciudadanos/enfLesiones/enfTransmisibles.htm.
[28]
Infección por VIH y SIDA en España Plan Multisectorial. Indicadores 2006. Disponible en: http://www.msc.es/ciudadanos/enfLesiones/enfTransmisibles/sida/planesEstrat/indicadores2006_3.pdf 2006.
[29]
Plan Nacional sobre Drogas. Disponible en: http://www.pnsd.msc.es
[30]
E.L. Schwartz, A.B. Brechbühl, P. Kahl, M.A. Miller, P.A. Selwyn, G.H. Friedland, et al.
Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infections.
J Acquir Immune Defic Syndr, 5 (1992), pp. 619-626
[31]
S.M. Clarke, F. Mulcahy, J. Tjia, H.E. Reynolds, S.E. Gibbons, M.G. Barry, et al.
Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users.
Clin Infect Dis, 33 (2001), pp. 1595-1597
[32]
S.M. Clarke, F.M. Mulcahy, J. Tjia, H.E. Reynolds, S.E. Gibbons, M.G. Barry, et al.
The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz.
Br J Clin Pharmacol, 51 (2001), pp. 213-217
[33]
R.D. Bruce, F.L. Altice, M.N. Gourevitch, G.H. Friedland.
Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications: Implications and Management for Clinical Practice.
J Acquir Immune Defic Syndr, 41 (2006), pp. 563-572
[34]
S.M. Robertson, S.R. Penzak, A.K. Pau.
Drug interactions in the management of HIV infection: an update.
Expert Opin Pharmacother, 8 (2007), pp. 2947-2963
[35]
G. Friedland, L. Andrews, T. Schreibman, S. Agarwala, L. Daley, M. Child, et al.
Lack of an effect of Atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction.
AIDS, 19 (2005), pp. 1635-1641
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos